AzTrials
AzTrials

Deep CariesPhase 2/3NCT06171776

Evaluation of Conservative Management of Teeth With Deep Cavitated Carious Lesions

A Phase 2/3 study testing RetroMTA, TheraCal and Fuji IX in people with Deep Caries and Pulp Exposure, Dental, run by Cairo University at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to compare postoperative pain of calcium silicate cement and resin-based tricalcium silicate (TheraCal LC) versus chemically Cured Glass Ionomer cement (FujiXI) in conservative management of very deep carious lesions by selective caries removal Read more about this study

Who is it for?
Ages 18 to 60 yearsHealthy volunteers can take part
Conditions the study is for
Deep Caries, Pulp Exposure, Dental
What is being tested?
RetroMTA, TheraCal and Fuji IX
Could I receive a placebo?
No, everyone receives an active treatment
How many people
90 participants
Where
1 siteEgypt
Study dates
1 Jan 2023to 1 Jan 2025
Phase
Phase 2/3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Patients male or female older than 18 y in good general health
  • A minimum of 1 deep carious lesion penetrating three-quarters or more into the dentine as identified with the periapical (PA) radiograph; 3-Clinically according to International Caries Detection and Assessment System (ICDAS II) score 4 (Clinical symptoms of reversible pulpitis)
  • 4. Positive pulp response to thermal stimulation (cold test) 5. No PA changes viewed on PA radiograph

Who cannot join

  • 1-Clinical symptoms of irreversible pulpitis requiring endodontic treatment 2. Presence of fistulas or swelling 3. Mobile teeth or tenderness to percussion 4. Anterior teeth with aesthetic concerns 5. Pregnant women, in view of requirements for radiographs 6. Patients younger than 18 y 7. Patients unable to give consent
  • -

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Omnia Magdy

    Cairo, 02

Other trials in Egypt

About this study

Official title: Evaluation of Conservative Management of Teeth With Deep Cavitated Carious Lesions Using Three Different Lining Materials-a Randomized Clinical Trial

The goal of this clinical trial is to compare postoperative pain of calcium silicate cement and resin-based tricalcium silicate (TheraCal LC) versus chemically Cured Glass Ionomer cement (FujiXI) in conservative management of very deep carious lesions by selective caries removal

Read the detailed description

p-Patients having Permanent posterior teeth with very deep carious lesions I 1 calcium silicate cement I 2= resin-based tricalcium silicate (TheraCal LC) C- chemically Glass Ionomer cement O- Outcome name Measuring Device Measuring Unit Primary1ry postoperative pain 1- Refrigerant spray (endo frost ) 2- Percussion (Marchi et al. 2006) 3- Palpation Binary Secondry2ry Peri-apical pathosis Digital radiograph (Hashem et al. 2015) Binary

T- one month, three months, six months,12 months,24 months evaluation S-Randomized clinical trial 7- Trial design: Randomized Controlled Trial. Trial type: single blind parallel arms design Trial framework: Equivalence frame, Allocation ratio: 1:1. Research question In patients having permanent posterior teeth with very deep carious lesions will calcium silicate cement or resin-based tricalcium silicate (TheraCal LC) in comparison to chemically cured glass ionomer cement result in clinical and radiographical success? Methods: Participants, interventions, and outcomes 8-Study Settings: This clinical trial will be held in the Faculty of Oral \& Dental Medicine Cairo University, Egypt.

9- Eligibility criteria:

  1. Eligibility Criteria of participants: Inclusion Criteria of participants:
  2. Patients male or female older than 18 y in good general health
  3. A minimum of 1 deep carious lesion penetrating three-quarters or more into the dentine as identified with the periapical (PA) radiograph; Clinically according to International Caries Detection and Assessment System (ICDAS II) score 4
  4. Clinical symptoms of reversible pulpitis
  5. Positive pulp response to electric pulp test or thermal stimulation
  6. No PA changes viewed on PA radiograph Exclusion Criteria of participants:
  7. Clinical symptoms of irreversible pulpitis requiring endodontic treatment
  8. Presence of fistulas or swelling
  9. Mobile teeth or tenderness to percussion
  10. Anterior teeth with aesthetic concerns
  11. Pregnant women, in view of requirements for radiographs
  12. Patients younger than 18 y
  13. Patients unable to give consent
  14. Exclusion criteria of the teeth: Teeth with symptoms of irreversible pulpitis including persistent dull throbbing pain, sharp spontaneous pain, or pain exacerbated by lying down will be excluded. In addition, patients will be withdrawn from the study if pulp exposure occurred during the baseline operative intervention.
  15. Assessor and Operator criteria: Operator: O.M. (PHD), Assessor: A.R. (PHD) 10a- Interventions: • Pre-operative clinical assessment :
  16. Thermal testing using Refrigerant spray (Endo Frost, Roeko, Langenau, Germany)
  17. percussion test
  18. Palpation and clinical examination for the signs of inflammation (pain, abscess, sinus tract, and mobility).
  19. PA radiographs using digital radiograph will be taken at baseline (T0) and will be assessed to exclude any signs of irreversible pulpitis (widening of periodontal ligament [PDL] or PA lesions). These tests were carried out at baseline, pre-operatively, and at 1 month , 3, 6,12 and 24-month in post-operative follow-up visits
  • Caries removal procedure: Local anesthesia will be given to the patient then complete isolation to the tooth using rubber dame the operator O.M. will open the enamel if needed using high speed hand piece (NSK, NSK America Corp,USA) with high speed diamond round bur (Standard shank Ø1.6mm x 19mm FG. Diamond medium grit) (komet Rock Hill, SC, United States) under copious irrigation. Then in caries removal from the walls carbon-steel rose-head bur (komet Rock Hill, SC, United States) in low speed hand piece (W\&H DentalwerkBürmoos GmbH, Bürmoos, Austria).Finally the deeper caries will be removed using spoon excavator (no 49, 61 or 73, Dentsply,Maillefer) leaving the last layer affected dentine without any direct pulp exposure (Clarkson et al., 2021) Intervention: RetroMTA (BioMTA, Seoul, Korea) and TheraCal LC (Bisco Inc., Schaumburg, IL, USA) *The material will be applied according to manufacturer instructions Comparator: GC Fuji IX GP® (GC America Inc, Alsip, IL,USA) *The material will be applied according to manufacturer instructions Final restoration application: Filtek™ Z250 Universal Restorative (3M Canada, London, Ontario Canada) Adhesive system: Scotchbond Universal Etchant (3M ESPE, St. Paul MN, USA) \& Single Bond Universal adhesive (3M ESPE, St. Paul MN, USA).
  • The material will be applied according to manufacturer instruction as follows: Etchant will be applied for 15 seconds then rinsed for 15 seconds, then cavity will be dried using gentle air stream. Adhesive material will be applied to the cavity and rubbed for 20 second, then will be air thinned using gentle air for 5 seconds and photo-cured for 20 seconds using LED light curing unit. After applying the adhesive, composite will be applied then photo-cured for 40 seconds using LED light curing unit. 11b-Restoration will be removed when there are any signs of leakage, fracture or sever postoperative pain due to pulpal response and will unergo endodontic treatment. 13- Radiographical assessment: digital periapical radiograph ( FONA XDC , FONA SRL, Assago, Italy ) will be tacken by A.R. at T0 (after the operative procedure) and after 1 month(T1), 3 (T3) ,6 ( T6) , 12( T12) and 24 ( T24) months using paralleling technique to standardize the final record for each patient then processed in ( DIGORA optime, sordexTuusula, Finland) . 11- Outcomes: outcomes criteria, measuring devices, scores, characteristics, measuring unite: Criterion M. device Score Characteristics M. unit 13- Recruitment: Patients will be recruited byA.R. from clinic of conservative dentistry department in Faculty of Oral \&Dental Medicine Cairo University, where there is a continuous and high patient flow from which eligible patients will be recruited to fulfill the eligibility criteria 1 week before intervention. Methods: Assignment of interventions Allocation: 15a- Sequence generation: Simple randomization will be done by generating numbers from 1:99 using Random Sequence Generator, Randomness and Integrity Services Ltd (https://www.random.org/) . No from 1-33 represents the first intervention and from 34-66 is second intervention and from 67-99 is the comparator. 15b- Allocation concealment: Operator O.M. will choose between numbers in an opaque sealed envelope, which will be arranged by A.R. who will not be involved in any of the phases of the clinical trial. The side to which intervention or control is assigned will be recorded on a computer by O.M. and all records of all patients will be kept with A.R 16- Blinding: The operator will not be blinded to material assignment because of the difference in the application protocol of the restorative materials, which prohibited blinding of the operator; however, assessors will be blinded to the material assignment. Methods: Data collection, management, and analysis 17a- Data collection methods:
  • Baseline data collection: For every patient medical and dental history will be taken. Examination charts will be filled by A.R
Being tested
RetroMTA, TheraCal, Fuji IX
Medical subject headings
Dental Pulp Exposure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RetroMTADrug

    Also called MTA

    calcium silicate lining material work as dentin substitute

  • TheraCalDrug

    Also called resin based calcium silicat

    calcium silicat material light cured

  • Fuji IXDrug

    Also called chemically cured glass

    filling material bonded chemically to the tooth structure

Study groups in NCT06171776
Study groupRoleWhat they receive
fuji XIActive comparatorchemically cured glass ionomer
Receives: Drug: Fuji IX
RetroMTAExperimentalcacium silicat cement
Receives: Drug: RetroMTA
Theracal LCExperimentalresin based calcium silicate cement
Receives: Drug: TheraCal

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. postoperative pain (binary)

    pain after restoration of teeth using cold test

    Measured: one week to 24 months

Secondary outcomes (1)
  1. periapical pathosis detection using digital periapical radiograph

    detection of periapical pathosis

    Measured: one week to 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Dec 2023
  2. Study start1 Jan 2023
  3. Primary completion1 Jan 2024 (estimated)
  4. Study completion1 Jan 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
90 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06171776
Sponsor's protocol ID
345
Status last verified
Dec 2023
First submitted
29 Nov 2023
Last updated
15 Dec 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing RetroMTA, TheraCal and Fuji IX in people with Deep Caries and Pulp Exposure, Dental, run by Cairo University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

postoperative pain (binary) (time frame: one week to 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Dec 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in